Abstract
The 2016 World Health Organization classification of tumors of the central nervous system was recently revised. Mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes and chromosome 1p/19q codeletion are especially important for both the integrated diagnosis and the determination of surgical strategy. To establish a method for intraoperative molecular diagnosis, a simple, rapid method was developed for the measurement of 2-hydroxyglutarate (2-HG), a specific oncometabolite formed in the presence of IDH gene mutation, using liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI–MS/MS). This method requires only 10 min to measure the level of 2-HG from tissue preparation to completion of examination. Using this method, the level of 2-HG was analyzed in 105 patients with diffuse infiltrating glioma, and showed that IDH mutated glioma had significantly higher level of 2-HG compared to IDH wild-type glioma. Receiver operating characteristic curve analysis showed the area under the curve, sensitivity, and specificity were 0.9815, 97.5, and 100%, respectively. In contrast, tumor grade and presence of chromosome 1p/19q codeletion in the IDH mutated glioma could not be predicted from the level of 2-HG. Measurement of 2-HG level using LC/ESI–MS/MS can provide rapid and accurate information of mutation status in the IDH gene.
Similar content being viewed by others
Abbreviations
- AUC:
-
Area under the curve
- 2-HG:
-
2-Hydroxyglutarate
- IDH:
-
Isocitrate dehydrogenase
- IS:
-
Internal standard
- LC/ESI–MS/MS:
-
Liquid chromatography/electrospray ionization tandem mass spectrometry
- LC–MS/MS:
-
Liquid chromatography tandem mass spectrometry
- ROC:
-
Receiver operating characteristic
- SRM:
-
Selected reaction monitoring
- WHO:
-
World Health Organization
References
Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification of tumours of the central nervous system. IARC Publications, Lyon
Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812
Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998
Capper D, Sahm F, Hartmann C et al (2010) Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 34:1199–1204
Horbinski C, Kelly L, Nikiforov YE et al (2010) Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 12:487–492
Wijnenga MMJ, French PJ, Dubbink HJ et al (2018) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological and molecular analysis. Neuro Oncol 20:103–112
Kawaguchi T, Sonoda Y, Shibahara I et al (2016) Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol 129:505–514
Beiko J, Suki D, Hess KR et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81–91
Nagashima H, Tanaka K, Sasayama T et al (2016) Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Neuro Oncol 18:1559–1568
Emir UE, Larkin SJ, de Pennington N et al (2016) Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations. Cancer Res 76:43–49
Choi C, Ganji SK, DeBerardinis RJ et al (2012) 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624–629
Pope WB, Prins RM, Albert Thomas M et al (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 107:197–205
Ohka F, Yamamichi A, Kurimoto M et al (2017) A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma. Brain Tumor Pathol 34:91–97
Yamamichi A, Kasama T, Ohka F et al (2016) An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. Sci Technol Adv Mater 17:618–625
Kanamori M, Kikuchi A, Watanabe M et al (2014) Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma. J Neurosurg 120:1288–1297
Ward PS, Patel J, Wise DR et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234
Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744
Santagata S, Eberlin LS, Norton I et al (2014) Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci USA 111:11121–11126
Jalbert LE, Elkhaled A, Phillips JJ et al (2017) Metabolic profiling of IDH mutation and malignant progression in infiltrating glioma. Sci Rep 7:44792
Shibahara I, Sonoda Y, Kanamori M et al (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551–561
Kanamori M, Kumabe T, Shibahara I et al (2012) Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases. Brain Tumor Pathol 30:15–27
Kanamori M, Kumabe T, Sonoda Y et al (2009) Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neurooncol 93:219–228
Pirro V, Alfaro CM, Jarmusch AK et al (2017) Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry. Proc Natl Acad Sci USA 114:6700–6705
Tietze A, Choi C, Mickey B et al (2017) Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. J Neurosurg. https://doi.org/10.3171/2016.10.JNS161793 (Epub 2017 Mar 3)
de la Fuente MI, Young RJ, Rubel J et al (2016) Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol 18:283–290
Ward PS, Lu C, Cross JR et al (2013) The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288:3804–3815
Acknowledgements
This work was supported by Grants-in-Aid for Scientific Research (no. 16K10749) from the Japan Society for the Promotion of Science.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Kanamori, M., Maekawa, M., Shibahara, I. et al. Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry. Brain Tumor Pathol 35, 90–96 (2018). https://doi.org/10.1007/s10014-018-0317-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10014-018-0317-0